Cardiovascular Drug-Eluting Stent Developers, Products, Status

Developers of Cardiovascular Drug-Eluting Stents

Company Stent Drug Status
Abbott Vascular Devices ZoMaxx Zotarolimus In clinicals; ZOMAXX II trial approved 6/05
Avantec Vascular (Goodman) Duraflex Pimecrolimus In development
Biosensors International BioMatrix Biolimus A9 In trials; Expects CE Mark in 2006
Boston Scientific Taxus Express2 Paclitaxel CE Mark 1/03; FDA approval 3/04
Boston Scientific Taxus Liberté Paclitaxel CE Mark 9/05 (launched 1/05); FDA approval expected mid-2006
Conor Medsystems CoStar Paclitaxel CE Marked 2/06
Conor Medsystems (Next-generation CoStar) Pimecrolimus Pimecrolimus licensed from Novartis in 3/06; Testing two devices: one loaded with pimecrolimus and another with both pimecrolimus and paclitaxel
Cordis (J&J) Cypher Sirolimus CE Mark; FDA approved, U.S. launch 4/03
Cordis Cypher Select Sirolimus CE Mark in 2003
Cordis Cypher Neo Sirolimus In development
CorNova (Undisclosed) (Undisclosed) In development
Devax Axxess Plus (bifurcated) Biolimus A9 In clinicals (positive first-in-man data reported 11/05)
DISA Vascular Stellium Paclitaxel In development
Estracure/Medivas/Picarus (Undisclosed) 17-(beta)-Estradiol In development
Guidant Xience V Everolimus CE Mark 1/06; European launch pending
Medtronic Endeavor Zotarolimus CE Mark 7/05; U.S. launch planned in 2007. RESOLUTE trial began 12/05
Occam International (subsidiary of Biosensors International) Axxion Paclitaxel CE Mark 7/05
Relisys Medical Devices (Undisclosed) Paclitaxel In clinicals
Sahajanand Medical Technologies (SMT) Infinnium Paclitaxel CE Mark 12/05
Sorin Biomedica Cardio Janus Flex Tacrolimus CE Mark; launched in Europe 2/06
Terumo Nobori Biolimus A9 Clinical trial launched 6/05
X-Cell Medical Ethos 17-(beta)-Estradiol In clinicals
Xtent Xtent Biolimus A9 In clinicals; European launch planned in 2007, U.S. in 2009

Note: CV Therapeutics and MIV Therapeutics (among others) are developing coatings for coronary drug stents.Source: MedMarket Diligence, LLCRelated Tags: , ,

Leave a Reply